Nan Ge

Thoracic Surgeon from 🇨🇳. Believe in surgery and favor multidisciplinary treatment. #UCSD visiting scholar in Surgery at #MooresCancerCenter 2022-2023.

[Ankit Bharat, MD FACS @AnkitBharatMD]

In 1963, Dr Hardy reported the first human lung transplant in JAMA—in a patient with lung cancer https://t.co/sdhhd8D5Sd. After decades of concern such as outlined in NEJM https://t.co/yjpN95agRN, cancers emerged as a contraindication for lung transplant.

Our @JAMA_current paper revisits this https://t.co/tbUX5TECeE. With modern staging, modified surgical technique, contemporary multidisciplinary case, we can provide hope for patients with Stage IV medically refractory cancers limited to the lungs.

[Victor Obi (RPh.T) @obi_phx]

🫁 Lung Transplant for Stage IV Lung Cancer? New Study Shows Promising Early Survival Results!
​For patients fighting advanced non-small cell lung cancer (NSCLC), standard non-surgical care isn't always enough. A groundbreaking new study focuses on a highly specific group: adults with medically refractory, lung-limited Stage IV NSCLC and respiratory failure.
​The findings offer a powerful new beacon of hope for extending early survival through highly targeted surgical intervention.
​📊 The Breakdown: Lung Transplant vs. Medical Management Alone
The study compared contemporary staging and specialized surgical techniques against the best available non-surgical care:
• Higher Early Survival: Patients who received a lung transplant showed significantly higher early overall survival rates compared to those on medical management alone.
• 1-Year Survival Milestone: Post-transplant, the 1-year survival rate for these Stage IV NSCLC patients was approximately 70%—proving to be completely noninferior to transplant recipients who didn't even have cancer.
​🔍 Who May Be Considered? (A Rigorously Defined Subset)
Because this is a complex intervention, it is strictly reserved for a highly carefully selected group of patients meeting these exact criteria:
​Lung-limited disease only (no evidence of extrathoracic metastasis).
​Adequate functional status and strong overall organ function.
​No active tobacco use and a demonstrated potential for strict medical adherence.
​Comprehensive evaluation and approval by a multidisciplinary transplant team.
​🗺️ The Transplant Journey:
The path involves a highly structured 5-step process: Comprehensive Evaluation ➡️ Candidate Selection ➡️ Surgical Transplant (using dissemination-minimizing techniques) ➡️ Recovery & Follow-up (immunosuppression and close monitoring) ➡️ Ongoing Assessment of survival and quality of life.
​🔮 Key Takeaway & Next Steps:
While these early results are highly promising, researchers note that more data is needed to confirm long-term survival benefits, evaluate extended quality of life outcomes, and refine candidate selection criteria even further.
​This multidisciplinary approach highlights a potential paradigm shift for a select group of patients fighting advanced lung cancer. 🩺✨
​#LungCancer #CancerResearch #Oncology #LungTransplant #MedicalBreakthroughs

[Nan Ge @NanGe_MD]

@Dr_AmerZeidan TOM HANKS

[Patrick Forde @FordePatrick]

Great to join med onc & surg colleagues from across China to discuss recent approval by China’s NMPA of neoadjuvant chemo-nivolumab for surgical lung cancer, several hundred pts treated in first few wks since approval! Thanks to all the pts from Asia who enrolled in CM816! #LCSM

[Nan Ge @NanGe_MD]

#Checkmate159 after 5 years.

[Patrick Forde @FordePatrick]

And here is a graphic of the five year outcomes!

[Chaolin Zhang @chaolinzhang]

Reviewing NIH grants now. A few things I learned and found to be very helpful as a reviewer: 0/n

[Natalie Vokes @NIVokes]

Happy to share that our work examining the benefits of adding chemotherapy to immunotherapy in NSCLC is now published in Nat Comms. We found that chemo adds no long-term or synergistic benefit to IO monotherapy. But! [1/4]
https://t.co/uSVxExefA2

[Nan Ge @NanGe_MD]

Unbelievable.

[Brendon Stiles @BrendonStilesMD]

@CatherineShuMD @StephenVLiu @AltorkiNasser @NEJM 59% wedge!

[Christopher A. Longhurst, MD @CALonghurst]

Dr. Firestein @ucsdactri says “the traditional double-blind, placebo-controlled trial is still the gold standard, but alternatives are emerging,” such as:

- Adaptive trials
- Real-world data
- “In silico” trials
- Open label trials
- Surrogate biomarkers

https://t.co/qLTYMby9fL

[Nan Ge @NanGe_MD]

@CatherineShuMD @jdoningtonmd @PeerView You had a great talk with Dr.Donington. I'm very pleased to talk with you afterwards.

[Nan Ge @NanGe_MD]

Congratulations to Dr @AltorkiNasser : Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer | NEJM https://t.co/s5RqaGwjhy

[UC San Diego Health @UCSDHealth]

It takes a village, especially when it comes to #cancer care. As the only @theNCI
designated Comprehensive Cancer Center in the region, the teams at Moores Cancer Center and #UCSDHealth clinics strive to provide personalized treatments. #WorldCancerDay https://t.co/Bb6oK5u8Tk

[John F. Lazar @jflazar]

Excited to announce the publication of our #roboticsurgery textbook: Robotic Surgery: Clinical Perceptions, Approaches, and Challenges by @novapresse . It is available for purchase at https://t.co/30keOI9LwK

[Yakup Ergün @dr_yakupergun]

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated ADAURA Trial @JCO_ASCO

4y DFS
Stage 2-3A➡️70% vs 29% (HR:0.23)
Stage 1B-3A➡️73% vs 38% (HR:0.27)

CNS recurrence
s2-3A➡️8% vs 14%
s1B-3A➡️6% vs 11%

G>3 AE
23% vs 14%

@OncoAlert
https://t.co/AFXtTgtYmu

[Nan Ge @NanGe_MD]

Cool!

[Jonathan Spicer MD PhD @DoctorJSpicer]

Oh man! I am so excited to finally be able to talk about this remarkable study led by amazing friend and outstanding scientist @loganawalsh from @McGillGCI, nearly 5 years in the making! This brilliant work of science has key implications for translation to lung cancer patients!

[Ezra Cohen @DrEzraCohen]

MRD in solid tumors can be measured and we must start to stratify patients using these sensitive tools.
https://t.co/zrUyAsnZQJ

[Nan Ge @NanGe_MD]

👏👏👏

[Patrick Forde @FordePatrick]

New approval for surgical lung cancer - immunotherapy now available either before or after surgery as option for nearly all patients - oncologist-patient discussions now more complicated but that is good news! Great work from Drs. @peters_solange @drMaryOBr 🇮🇪 & our pts! #LCSM

[Nan Ge @NanGe_MD]

@DrSidMukherjee brand new #thesongofthecell book. 👏👏👏

[Siddhartha Mukherjee @DrSidMukherjee]

Tour schedule for the Song of the Cell .....

[Nan Ge @NanGe_MD]

@Alfdoc2 @LungSummit @PatelOncology @peters_solange @JairBar4 @MdCurioni @StephenVLiu @NReguart @DrJNaidoo @JordiRemon @OncoViews Already registered :-)